nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
AI-based language models powering drug discovery and development
|
Liu, Zhichao |
|
|
26 |
11 |
p. 2593-2607 |
artikel |
2 |
A new approach to treat type 2 diabetes – Targeting a non-insulin dependent pathway
|
Ekman Ryding, Alexandra |
|
|
26 |
11 |
p. 2487-2488 |
artikel |
3 |
Artificial intelligence and the future of life sciences
|
Leite, Michel L. |
|
|
26 |
11 |
p. 2515-2526 |
artikel |
4 |
Brain safety concerns of nanomedicines: The need for a specific regulatory framework
|
Szabat-Iriaka, Bartlomiej |
|
|
26 |
11 |
p. 2502-2507 |
artikel |
5 |
Contents page 1
|
|
|
|
26 |
11 |
p. i |
artikel |
6 |
Converging global crises are forcing the rapid adoption of disruptive changes in drug discovery
|
Treherne, J. Mark |
|
|
26 |
11 |
p. 2489-2495 |
artikel |
7 |
De novo molecular design and generative models
|
Meyers, Joshua |
|
|
26 |
11 |
p. 2707-2715 |
artikel |
8 |
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants
|
Gulati, Karan |
|
|
26 |
11 |
p. 2734-2742 |
artikel |
9 |
Drugging the ‘undruggable’. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods
|
Radaeva, Mariia |
|
|
26 |
11 |
p. 2660-2679 |
artikel |
10 |
Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises
|
Amaral, Rafael |
|
|
26 |
11 |
p. 2608-2618 |
artikel |
11 |
Harnessing the power of microphysiological systems for COVID-19 research
|
Kleinstreuer, Nicole |
|
|
26 |
11 |
p. 2496-2501 |
artikel |
12 |
Hypoxia and the integrated stress response promote pulmonary hypertension and preeclampsia: Implications in drug development
|
Hu, Xiang-Qun |
|
|
26 |
11 |
p. 2754-2773 |
artikel |
13 |
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
|
Chavda, Vivek P. |
|
|
26 |
11 |
p. 2619-2636 |
artikel |
14 |
m6A RNA methylation and beyond – The epigenetic machinery and potential treatment options
|
Garbo, Sabrina |
|
|
26 |
11 |
p. 2559-2574 |
artikel |
15 |
Methods to improve the immunogenicity of plasmid DNA vaccines
|
Eusébio, Dalinda |
|
|
26 |
11 |
p. 2575-2592 |
artikel |
16 |
Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation
|
Zwart, Tom C. |
|
|
26 |
11 |
p. 2527-2546 |
artikel |
17 |
Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment
|
Matos, Bárbara |
|
|
26 |
11 |
p. 2680-2698 |
artikel |
18 |
Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target
|
Gao, Yongzhi |
|
|
26 |
11 |
p. 2699-2706 |
artikel |
19 |
Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer
|
Liao, Zi-Xian |
|
|
26 |
11 |
p. 2508-2514 |
artikel |
20 |
Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization
|
Wang, Kai |
|
|
26 |
11 |
p. 2743-2753 |
artikel |
21 |
Seeding drug discovery: Telomeric tankyrase as a pharmacological target for the pathophysiology of high-altitude hypoxia
|
Miglani, Manjula |
|
|
26 |
11 |
p. 2774-2781 |
artikel |
22 |
The optimization of combinatorial drug therapies: Strategies and laboratorial platforms
|
Wang, Boqian |
|
|
26 |
11 |
p. 2646-2659 |
artikel |
23 |
The search for inhibitors of macrodomains for targeting the readers and erasers of mono-ADP-ribosylation
|
Fu, Wei |
|
|
26 |
11 |
p. 2547-2558 |
artikel |
24 |
Three ‘D’s: Design approach, dimensional printing, and drug delivery systems as promising tools in healthcare applications
|
Rahman, Mahfoozur |
|
|
26 |
11 |
p. 2726-2733 |
artikel |
25 |
Thymoquinone: A small molecule from nature with high therapeutic potential
|
Malik, Safiya |
|
|
26 |
11 |
p. 2716-2725 |
artikel |
26 |
Triple helices’ perspectives on the availability of human and financial capital for biopharmaceutical innovation in select Central European ecosystems
|
Williams, David R. |
|
|
26 |
11 |
p. 2637-2645 |
artikel |